Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy (NCT03701308)

🧪 Interventions in This Study

• Cytarabine (DRUG)
• Daunorubicin (DRUG)
• Uproleselan (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Diagnosis of acute myeloid leukemia (AML) based on 2017 World Health Organization (WHO) criteria excluding acute promyelocytic leukemia with PML-RARA.
2. Note: Patients with myeloid sarcoma without bone marrow involvement, acute leukemia of ambiguous lineage or blast transformation of chronic myelogenous leukemia (CML) are not eligible.
3. No activating mutation in the Fms-like tyrosine kinase-3 (FLT3) defined as a ratio of mutant to wild-type allele \>= 0.05 by capillary electrophoresis or a variant allele fraction of \>= 5% by next generation sequencing from either bone marrow or peripheral blood.
4. No evidence of central nervous system (CNS) involvement of AML.
5. No prior chemotherapy for myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) or AML including hypomethylating agents (e.g. azacitidine and decitabine), ruxolitinib or lenalidomide with the following exceptions:
6. Emergency leukapheresis
7. Hydroxyurea
8. Growth factor/cytokine support
9. All-trans retinoic acid (ATRA)
10. Single dose of intrathecal cytarabine and/or methotrexate for patients undergoing lumbar puncture to evaluate for CNS involvement.
11. Age \>= 60 years.
12. Total bilirubin =\< 3 x upper limit of normal (ULN)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (188 Sites)

Showing the first 25 of 188 sites.

• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• Community Cancer Institute — Clovis, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Loma Linda University Medical Center — Loma Linda, California
• Cedars Sinai Medical Center — Los Angeles, California
• Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
• Yale University — New Haven, Connecticut
• Delaware Clinical and Laboratory Physicians PA — Newark, Delaware
• Helen F Graham Cancer Center — Newark, Delaware
• Medical Oncology Hematology Consultants PA — Newark, Delaware
• Christiana Care Health System-Christiana Hospital — Newark, Delaware
• Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
• Saint Luke's Cancer Institute - Boise — Boise, Idaho
• Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
• Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
• Walter Knox Memorial Hospital — Emmett, Idaho
• Idaho Urologic Institute-Meridian — Meridian, Idaho
• Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
• Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
• Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho
• Illinois CancerCare-Bloomington — Bloomington, Illinois
• Illinois CancerCare-Canton — Canton, Illinois
• Memorial Hospital of Carbondale — Carbondale, Illinois
• SIH Cancer Institute — Carterville, Illinois
• Illinois CancerCare-Carthage — Carthage, Illinois

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myeloid Leukemia

• PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
• ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia — Charlotte, North Carolina
• Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
• A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia — Basking Ridge, New Jersey
• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML — Phoenix, Arizona

Explore by condition: All Acute Myeloid Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.